Veeral Sheth to Angiogenesis Inhibitors
This is a "connection" page, showing publications Veeral Sheth has written about Angiogenesis Inhibitors.
Connection Strength
1.109
-
An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017 02 01; 48(2):100-104.
Score: 0.492
-
Use of intravitreous bevacizumab to treat macular edema in West Nile virus chorioretinitis. Arch Ophthalmol. 2012 Mar; 130(3):396-8.
Score: 0.350
-
Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022; 7(1):e000957.
Score: 0.175
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
Score: 0.049
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
Score: 0.044